lyophilisation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
=== Toxicity === Tau causes toxic effects through its accumulation inside cells. Many enzymes are involved in toxicity mechanism such as PAR-1 kinase. This enzyme stimulates phosphorylation of serine 262 and 356, which in turn leads to activate other kinases (GSK-3 and CDK5) that cause disease-associated phosphoepitopes. The degree of toxicity is affected by different factors, such as the degree of microtubule binding. Toxicity could also happen by neurofibrillary tangles (NFTs), which leads to cell death and cognitive decline.
W.E.S. Turner; F. Winks (1926). Journal of the Society of Glass Technology. 102. {{cite journal}}: Missing or empty |title= (help) F. Janowski; W. Heyer (1982). Poröse Gläser – Herstellung, Eigenschaften und Anwendungen. VEB Deutscher Verlag für Grundstoffindustrie, Leipzig. F. Friedel (2001). Diplomarbeit, Halle. {{cite book}}: Missing or empty |title= (help) F. Janowski (1993). Maschinenmarkt. 99: 28–33. {{cite journal}}: Missing or empty |title= (help) O.S. Moltschanowa (1957). Glas und Keramik. 14: 5–7. {{cite journal}}: Missing or empty |title= (help) F. Wolf; W. Heyer (1968). "Modifizierte poröse gläser als träger in der gaschromatographie". J. Chromatogr. 35: 489–496. doi:10.1016/s0021-9673(01)82414-6. Schuller GmbH (1999). "Life Sciences – Mehr als nur poröse Gläser (Anwenderbericht)". LABO9: 26–28. SCHOTT Information. 53. 1990. {{cite journal}}: Missing or empty |title= (help) M. Hermann (VitraBio GmbH) (2007). "Verfahren zur Herstellung eines porösen Glases und Glaspulvers und Glaswerkstoff zum Ausführen des Verfahrens". WO 098778. {{cite journal}}: Cite journal requires |journal= (help) P. W. McMillan; C. E. Matthews (1976). "Microporous glasses for reverse osmosis". J. Mater. Sci. 11 (7): 1187–1199. Bibcode:1976JMatS..11.1187M. doi:10.1007/bf00545135. S2CID 137379816. F. Janowski; A. Sophianos; F. Wolf (1979). "The role of acidity of MoO3−SiO2 and WO3−SiO2 catalysts". React. Kinet. Catal. Lett. 12 (2): 443. doi:10.1007/BF02071904. S2CID 102283765. G.R. Gavalas; C.E. Megiris; S.W. Nam (1989). "Deposition of H2-permselective SiO2 films". Chem. Eng. Sci.
In cancerous cells, initiation factors assist in cellular transformation and development of tumors. The survival and growth of cancer is directly related to the modification of initiation factors and is used as a target for pharmaceuticals. Cells need increased energy when cancerous and derive this energy from proteins. Over-expression of initiation factors correlates with cancers, as they increase protein synthesis for proteins needed in cancers. Some initiation factors, such as eIF4E, are important in synthesizing specific proteins needed for the proliferation and survival of cancer. The careful selection of proteins ensures that proteins that are usually limited in translation and only proteins needed for cancer cell growth will be synthesized. This includes proteins involved in growth, malignancy, and angiogenesis. The eIF4E factor, along with eIF4A and eIF4G, also play a role in transitioning benign cancer cells to metastatic. The largest initiation factor, eIF3, is another significant initiation factor in human cancers. Due to its role in creating the 43S pre-initiation complex, it helps to bind the ribosomal subunit to the mRNA. The initiation factor has been linked to cancers through over-expression. For example, one of the thirteen eIF3 proteins, eIF3c, interacts with and represses proteins used in tumor suppression. Limited expression of certain eIF3 proteins, such as eIF3a an eIF3d, has been proven to decrease the vigorous growth of cancer cells. The over-expression of eIF3a has been linked to breast, lung, cervix, esophagus, stomach, and colon cancers.
The densities of the two phases must also be sufficiently different so that the phases will move past each other in the column. Many DCCC solvent systems contain both chloroform and water. The solvent system used in the seminal publication was made from chloroform, acetic acid, and aqueous 0.1 M hydrochloric acid. Many subsequent solvents systems were made with chloroform, methanol, and water which is sometimes represented as a ChMWat solvent system. Solvent systems formulated with ''n''-butanol, water and a modifier such as acetic acid, pyridine or n-propanol have also enjoyed some success in DCCC. In some cases, non-aqueous biphasic solvent systems such as acetonitrile and methanol have been utilized. The main difference between DCCC and other types of countercurrent chromatography techniques is that there is no vigorous mixing of phases to enhance the mass transfer of compounds that allows them to distribute between the two phases. In 1951 Kies and Davis described an apparatus similar to the DCCC. They created a series of open tubes that were arranged in a cascade to either drip a more dense phase through a less dense stationary phase or, conversely, a less dense phase could be introduced into the bottom of the tube to dribble through the more dense phase. In 1954, a fractionation column was introduced by Kepes the resembled a CCC column divided into chambers with perforated plastic disks. Similar DCCC-type instruments have been created by A. E. Kostanyan and collaborators which employ vertical columns that are divided into partitions with porous disks.
There are many challenges surrounding human remains accessioned by museums, including legal complications involved in dealing with human remains, involvement of living relatives or tribes, and potential repatriation and issues such as the Native American Graves Protection and Repatriation Act of 1990 (NAGPRA). NAGPRA requires any federal or federally-funded institution, with the exception of the Smithsonian Institution, to submit full inventories of their Native American funerary and sacred objects and human remains and to repatriate these objects to their tribe of origin should a request be made to do so. Should a museum possess human remains which have a direct living relative or group (Native American or otherwise), it is their ethical obligation to involve these individuals in the care and treatment of the remains. Acquisition of human remains by museums can happen in a number of ways, some of which are considered to be unethical today. Many museums have human remains in their collections which have been there for over a hundred years, in which case they may likely have been acquired in ethically or morally unsound ways. This has led to growing concerns that the display of human remains has become depersonalised, by continuing to keep them in collections. Most institutions and museum associations have their own policies on the acquisition of human remains. Some guidelines for the care of human remains including acceptable means of acquisition can be found below.
Sources: en.wikipedia.org
In December 2021, Newsom announced his intention to make California a "sanctuary" for abortion, which included possibly paying for procedures, travel, and lodging for out-of-state abortion seekers, if the procedure is banned in Republican-led states. In March 2022, he signed a bill requiring private health insurance plans in the state to fully cover abortion procedures by eliminating associated co-pays and deductibles and increasing insurance premiums. In February 2023, Newsom organized the Reproductive Freedom Alliance of state governors supportive of abortion and reproductive rights. After Walgreens announced in March 2023 that it would refuse to dispense abortion pills in the 21 states where it is illegal, Newsom tweeted, "California won't be doing business with @walgreens – or any company that cowers to the extremists and puts women's lives at risk, we're done." He also said that Walgreens was giving in to "right-wing bullies" and that he would determine how California could cut ties with it. He indicated that he wanted to cancel Walgreens's $54 million contract with the California state prison system. Walgreens also receives $1.5 billion for filling prescriptions for the 15 million people enrolled in the state's Medi-Cal program (California's version of Medicaid). Legal experts said that federal Medicaid laws do not allow health plans to disqualify providers for reasons other than fraud or contract violations, provisions that have prevented conservative states from blocking Medicaid spending to Planned Parenthood clinics.
=== War on Want === From November 1983 to 1987, Galloway was the general secretary of War on Want, a British charity campaigning against poverty worldwide. In this post he travelled widely, and wrote eye-witness accounts of the famine in Eritrea in 1985 which were published in The Sunday Times and The Spectator. His deputy at the charity, Simon Stocker, recalled: "If you went into a fight with George, you knew you would never walk out with a win." On 28 October 1986, the Daily Mirror, in a front-page story by Alastair Campbell, alleged Galloway had spent £20,000 in expenses and had been "enjoying a life of luxury". An internal investigation, and later, an independent auditor, both cleared him of the accusation of any misuse of funds, although he did repay £1,720 in contested expenses. The official history of War on Want comments about Galloway that "even though the problems were not all of his own making, his way of dealing with them heightened tensions".
== Production and reactions == HMF was first reported in 1875 as an intermediate in the formation of levulinic acid from sugar and sulfuric acid. This remains the classical route, with 6-carbon sugars (hexoses) such as fructose undergoing acid catalyzed poly-dehydration. When hydrochloric acid is used 5-chloromethylfurfural is produced instead of HMF. Similar chemistry is seen with 5-carbon sugars (pentoses), which react with aqueous acid to form furfural.
Charcot–Marie–Tooth (CMT) disease is an inherited neurological disorder primarily caused by genetic mutations that disrupt critical proteins within peripheral nerves. These mutations predominantly affect proteins essential for the structure and function of the myelin sheath, including peripheral myelin protein 22 (PMP22), myelin protein zero (P0/MPZ), connexin32 (Cx32/GJB1), and periaxin (PRX), leading to demyelination. Additionally, mutations in proteins involved in axonal integrity, such as neurofilament light chain (NF-L), dynamin 2 (DNM2), ganglioside-induced differentiation-associated protein 1 (GDAP1), and mitofusin 2 (MFN2), can cause axonal forms of CMT. Due to the close interaction between Schwann cells (which produce myelin) and axons, mutations affecting Schwann cells often result in secondary axonal degeneration, further complicating disease progression. Ultimately, the pathogenesis of CMT involves the disruption of essential cellular processes, including protein synthesis, sorting, intracellular transport, protein degradation, and mitochondrial function, highlighting the complex molecular mechanisms underlying this disorder.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.